AI assistant
ARS Pharmaceuticals, Inc. — Director's Dealing 2024
Nov 27, 2024
32159_dirs_2024-11-27_7b6669aa-3904-4fd2-ab97-07156247dba1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-11-25
Reporting Person: Chakma Justin (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-11-25 | Common Stock | S | 32814 | $14.0008 | Disposed | 203566 | Direct |
| 2024-11-26 | Common Stock | S | 42186 | $14.0466 | Disposed | 161380 | Direct |
| 2024-11-27 | Common Stock | S | 25000 | $14.39 | Disposed | 136380 | Direct |
Footnotes
F1: The weighted average sale price for the transaction reported was $14.0008, and the range of prices were between $14.00 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F2: The weighted average sale price for the transaction reported was $14.0466, and the range of prices were between $13.95 and $14.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.